Gut and lung bacteria could predict immunotherapy success in lung cancer
NCT ID NCT04063501
First seen Jan 11, 2026 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This study looks at 48 adults with advanced lung cancer who are about to start immunotherapy. Researchers will collect samples from the lungs, stool, and blood before and after treatment to see if certain bacteria are linked to better outcomes. The goal is to understand why some people respond well to immunotherapy while others do not.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors predict which lung cancer patients will benefit from immunotherapy, leading to more personalized treatment plans.
What could go wrong
This is an early observational study with only 48 participants, so results may not apply to all patients. It does not test a new treatment, so no direct benefit to participants.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.